Redx Pharma plc Distribution to Unsecured Creditors (8925O)
August 24 2017 - 4:42AM
UK Regulatory
TIDMREDX
RNS Number : 8925O
Redx Pharma plc
24 August 2017
24 August 2017
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION
IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Permission granted for distribution to Unsecured Creditors
Redx, the drug discovery and development company, announces that
Jason Baker and Miles Needham of FRP Advisory LLP, joint
administrators of the Company and of its subsidiary, Redx Oncology
Limited ("Oncology") (together, the "Companies") have been granted
permission by the High Court to make a distribution to unsecured
creditors of the Companies. The Joint Administrators will shortly
be sending unsecured creditors notices of intended dividend,
following which claims will be adjudicated and distributions made.
All unsecured creditors will be paid in full (subject to
adjudication). This is a significant step towards the anticipated
rescue of the Companies as going concerns and the termination of
the Administrations. A PDF copy of the Order is attached to this
notice.
Click on, or paste the following link into your web browser, to
view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/8925O_-2017-8-24.pdf
For further information, please contact:
Redx Pharma Plc (in administration)
Contact for the Joint Administrators: T: + 44 203
Chris French 005 4000
James Rossiter
Cantor Fitzgerald Europe (Nomad & T: +44 20
Broker) 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
About Redx Pharma Plc (in administration)
Company website: redxpharma.com
Jason Baker and Miles Needham have been appointed as joint
administrators of Redx Pharma plc (in administration). The
company's affairs, business and property are being managed by the
joint administrators.
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a broad portfolio of proprietary drug programs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPIMPTMBJTMPR
(END) Dow Jones Newswires
August 24, 2017 04:42 ET (08:42 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2023 to Apr 2024